Background: Focal Segmental Glomerulosclerosis (FSGS) is a
rare condition that is detected in only 9% of all kidney biopsies.
with consistent rates in recent years. This study aimed to
investigate the effect of Low-Dose Colchicine (LoDoCo) (0.5mg
once daily) as Add-On therapy on the response and progression
of steroid resistant primary FSGS in patients receiving standard
care. Methods: The study was carried on 40 patients with
primary FSGS resistant to corticosteroids admitted to
Nephrology Department at Benha University Hospitals. Results:
The eGFR was significantly increased during follow-up
(P